The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
Open accessAbstract
BACKGROUND The concept of the use of MRI for image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer was introduced 20 years ago. Here, we report on EMBRACE-I, which aimed to evaluate local tumour control and morbidity after chemoradiotherapy and MRI-based IGABT. METHODS EMBRACE-I was a prospective, observational, multicentre cohort study. Data from patients from 24 centres in Europe, Asia, and North America were prospectively collected. The inclusion criteria were patients older than 18 years, with biopsy-proven squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, The International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA disease or FIGO stage IVB disease restricted to paraaortic lymph metastasis below the L1-L2 interspace, suitable for curative treatment. Treatment consisted of chemoradiotherapy (weekly intravenous cisplatin 40 mg/m2, 5-6 cycles, 1 day per cycle, plus 45-50 Gy external-beam radiotherapy delivered in 1·8-2 Gy fractions) followed by MRI-based IGABT. The MRI-based IGABT target volume definition and dose reporting was according to Groupe Européen de Curiethérapie European Society for Radiation Oncology recommendations. IGABT dose prescription was open according to institutional practice. Local control and late morbidity were selected as primary endpoints in all patients available for analysis. The study was registered with ClinicalTrials.gov, NCT00920920. FINDINGS Patient accrual began on July 30, 2008, and closed on Dec 29, 2015. A total of 1416 patients were registered in the database. After exclusion for not meeting patient selection criteria before treatment, being registered but not entered in the database, meeting the exclusion criteria, and being falsely excluded, data from 1341 patients were available for analysis of disease and data from 1251 patients were available for assessment of morbidity outcome. MRI-based IGABT including dose optimisation was done in 1317 (98·2%) of 1341 patients. Median high-risk clinical target volume was 28 cm3 (IQR 20-40) and median minimal dose to 90% of the clinical target volume (D90%) was 90 Gy (IQR 85-94) equi-effective dose in 2 Gy per fraction. At a median follow-up of 51 months (IQR 20-64), actuarial overall 5-year local control was 92% (95% CI 90-93). Actuarial cumulative 5-year incidence of grade 3-5 morbidity was 6·8% (95% CI 5·4-8·6) for genitourinary events, 8·5% (6·9-10·6) for gastrointestinal events, 5·7% (4·3-7·6) for vaginal events, and 3·2% (2·2-4·5) for fistulae. INTERPRETATION Chemoradiotherapy and MRI-based IGABT result in effective and stable long-term local control across all stages of locally advanced cervical cancer, with a limited severe morbidity per organ. These results represent a positive breakthrough in the treatment of locally advanced cervical cancer, which might be used as a benchmark for clinical practice and all future studies. FUNDING Medical University of Vienna, Aarhus University Hospital, Elekta AB, and Varian Medical Systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00048-8 · Cited by 2,154
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
Ramirez, P. T., Frumovitz, M., Pareja, R., Lopez, A., Vieira, M., Ribeiro, R., Buda, A., Yan, X., Shuzhong, Y., Chetty, N., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806395 · Cited by 1,874
Concato, J., Peduzzi, P., Holford, T. R., & Feinstein, A. R. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00510-2 · Cited by 797
Sturdza, A., Pötter, R., Fokdal, L. U., Haie-Meder, C., Tan, L. T., Mazeron, R., Petric, P., Šegedin, B., Jurgenliemk-Schulz, I. M., Nomden, C., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.03.011 · Cited by 715
Self-citationTrends in the Utilization of Brachytherapy in Cervical Cancer in the United States
Han, K., Milosevic, M., Fyles, A., Pintilie, M., & Viswanathan, A. N. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.05.033 · Cited by 553
Cibula, D., Fischerova, D., Potter, R., Planchamp, F., Querleu, D., Avall-Lundqvist, E., Meder, C. H., Kohler, C., Landoni, F., Lax, S., et al. (2018) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001216 · Cited by 489
Self-citationBentzen, S. M., Dörr, W., Gahbauer, R., Howell, R. W., Joiner, M. C., Jones, B., Jones, D. T. L., van der Kogel, A. J., Wambersie, A., & Whitmore, G. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.10.006 · Cited by 244
Self-citationRijkmans, E. C., Nout, R. A., Rutten, I. H. H. M., Ketelaars, M., Neelis, K. J., Laman, M. S., Coen, V. L. M. A., Gaarenstroom, K. N., Kroep, J. R., & Creutzberg, C. L. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.08.027 · Cited by 237
Self-citationShrivastava, S., Mahantshetty, U., Engineer, R., Chopra, S., Hawaldar, R., Hande, V., Kerkar, R. A., Maheshwari, A., Shylasree, T. S., Ghosh, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5179 · Cited by 192
Self-citationUppal, S., Gehrig, P. A., Peng, K., Bixel, K. L., Matsuo, K., Vetter, M. H., Davidson, B. A., Cisa, M. P., Lees, B. F., Brunette, L. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03012 · Cited by 175
Cited by
Cancer of the cervix uteri: 2021 update
Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13865 · Cited by 554
Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., Acevedo, A., Sukhin, V., Cloven, N., Pereira de Santana Gomes, A. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00317-9 · Cited by 410
Self-citationCancer of the cervix uteri: 2025 update
Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70277 · Cited by 58
Metadata
- Authors
- Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., Fokdal, L. U., Sturdza, A. E., Hoskin, P., Mahantshetty, U., Segedin, B., Bruheim, K., Huang, F., Rai, B., Cooper, R., van der Steen-Banasik, E., Van Limbergen, E., Pieters, B. R., Tan, L.-T., Nout, R. A., De Leeuw, A. A. C., Ristl, R., Petric, P., Nesvacil, N., Kirchheiner, K., Kirisits, C., Lindegaard, J. C., Chargari, C., Dumas, I., Lowe, G., Swamidas, J., Hudej, R., Paulsen Hellebust, T., Menon, G., Oinam, A. S., Bownes, P., Christiaens, M., De Brabandere, M., Janssen, H., Oosterveld, B., Koedooder, K., Langeland Marthinsen, A. B., Sundset, M., Whitney, D., Ketelaars, M., Lutgens, L. C. H. W., Reinniers, B., Mora, I., Villafranca, E., Antal, G., Hadjiev, J., Bachand, F., Batchelar, D., Erickson, B., Rownd, J., Jacobson, G., Kim, Y., Anttila, M., Palmgren, J.-E., An, J., Assenholt, M. S., Banerjee, S., Bentzen, S., Berger, T., Dankulchai, P., Diendorfer, T., Dilworth, I., Dimopoulos, J., Dörr, E., Ecker, S., Federico, M., Fidarova, E., Fortin, I., Georg, P., Gora, J., Hegazy, N., Jastaniyah, N., Jensen, N. B. K., Liederer, T., Majercakova, K., Misimovic, D., Motisi, L., Najjari Jamal, D., Nkiwane, K., Schwartz-Vittrup, A., Serban, M., Smet, S., Spampinato, S., Trnkova, P., Valgma, M., Westerveld, H., Wong, J. S. Y., & Yoshida, K.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 22
- Issue
- 4
- Pages
- 538-547
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3142845014
- Cited by
- 670
- References
- 13
- FWCI
- 80.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30753-1
- The paper
- Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., Fokdal, L. U., Sturdza, A. E., Hoskin, P., Mahantshetty, U., Segedin, B., Bruheim, K., Huang, F., Rai, B., Cooper, R., van der Steen-Banasik, E., Van Limbergen, E., Pieters, B. R., Tan, L.-T., Nout, R. A., . . . Yoshida, K. (2021). MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30753-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.